OHE has appointed six Visiting Fellows and Senior Visiting Fellows, bringing with them a wealth of knowledge and expertise to be actively involved in OHE’s research programme.
Alastair Fischer Ph.D. has had a long career in statistics, economics and public health. He has a BSc from the University of Adelaide majoring in Pure Mathematica and Statistics, a BEc from the Australian National University and a PhD from the University of Adelaide.
He spent 5 years designing and maintaining sample surveys at the Australian Bureau of Statistics in Canberra before returning to Adelaide as a Senior Lecturer in Economics. His research interests during that time covered experimental economics, voting and elections, and the diffusion of innovations. After migrating to the UK in 1996, he taught economics in Cambridge at Trinity College and the University of Cambridge, and in the following year took up a Senior Lectureship in health economics at St George’s Medical School, University of London in the Department of Community Medicine. He was one of the first two health economists to be employed by the National Institute of Clinical Excellence (NICE) where he remained for 16 years, first in the economic evaluation of drugs and then a longer period in Public Health. His main research interests have been in ambulance economics, economics of diagnosis and the methodology involved in evaluating the prevention of ill-health.
He left NICE in 2016 to become Principal Health Economist at OHE and in 2017 became a Visiting Fellow at OHE, where his main interest is to continue work on methodology.
Professor Lou Garrison
Lou Garrison, PhD, is Professor in the Pharmaceutical Outcomes Research and Policy Program in the School of Pharmacy, and Adjunct Professor in the Departments of Global Health and Health Services at the University of Washington.
Dr. Garrison received a BA in Economics from Indiana University, and a PhD in Economics from Stanford University. He has more than 100 publications in peer-reviewed journals. His research interests include national and international health policy issues related to personalized medicine, benefit-risk analysis, insurance, pricing, reimbursement, and risk-sharing agreements, as well as the economic evaluation of pharmaceuticals, diagnostics, devices, surgical procedures, and vaccines, particularly as related to organ transplantation, influenza, measles, obesity, and cancer.
He is faculty advisor for the UW ISPOR Student Chapter, and is ISPOR President-elect for 2016-17.
Christopher Henshall Ph.D. has worked in universities, research funding bodies and the UK Civil Service, including positions at the UK Medical Research Council, the Department of Health and the NHS in England (where as Under Secretary he was involved in establishing the NHS R&D Budget, the NHS HTA Programme and the National Institute for Health and Care Excellence - NICE), the Department of Trade and Industry (where he was responsible for UK science and innovation policy and funding), and the University of York (where as Pro Vice Chancellor he was responsible for promoting enterprise and innovation and links with government and businesses, and served as Chair of the York Health Economics Consortium).
He was the Founding President of Health Technology Assessment International (HTAi), Chair of the HTAi Policy Forum from 2005-7 and 2011-16, and Chair of the HTAi Asia HTA Policy Forum from 2013-16. Other recent positions include Board Director of Alberta Innovates (the public funder of research and innovation in the Province of Alberta, Canada), Associate Professor in the Health Economics Research Group at Brunel University London, and Honorary Fellow at the Centre for Health Economics at the University of York (UK). He was awarded the David H Banta Distinguished Career Award by HTAi in 2017.
Mike's main research interests lie in the development, validation, and interpretation of patient-reported outcome (PRO) measures, particularly in younger populations, as well as the assessment of health state preferences and the use of qualitative research and consensus techniques in PRO development.
Mike has extensive experience in the field of patient-reported outcomes and health technology assessment and has worked in several public agencies, including the Catalan Institute of Public Health, the Catalan Agency for Health Technology Assessment, and the Barcelona Municipal Institute for Medical Research, as well as in the private sector. He currently runs his own consulting company in Spain.
A senior member of the EuroQol Group and an elected member of its executive committee, Mike has been heavily involved in the development of translated versions of the EQ-5D and in producing and testing versions for use in younger populations.
Mike holds an MSc in Bioethics and Law from the University of Barcelona and a BSc in Philosophy from the University of Hull in the UK. He has more than 150 publications in peer-reviewed journals.
Mike has been working in close collaboration with OHE for over 5 years, contributing to OHE’s research and consulting projects on patient reported outcomes.
Sarah Karlsberg is an Economist at NHS Improvement, where she works on issues facing the UK provider sector and the wider health and care system. As part of the Economics team, she delivers research that aims to improve operational performance, quality of care and financial performance, and to inform strategic change in the NHS.
Prior to joining NHS Improvement, Sarah was an Economist at OHE. In this role, she focused on the economics of health technology assessment (particularly cost-effectiveness thresholds), prioritisation and decision-making in the NHS, the role of incentives for health care providers, the economics of antimicrobial resistance and long-term care for the elderly. She has several published articles and has presented at various health economics conferences including ISPOR, EuHEA and HESG. Sarah has a BSc (First class) in Economics from the University of Bristol and an MSc (Distinction) in Economic Policy from University College London.
Jorge Mestre-Ferrandiz graduated with a PhD in Economic Analysis from the University Autonoma of Barcelona in 2001. He now works as an independent economics consultant, having spent nearly 15 years at The Office of Health Economics, starting as an Industrial Economist and finishing as Director of Consulting, in December 2016.
Dr Mestre-Ferrandiz has published over 50 papers on health economics and is regularly invited to speak on related topics at academic and commercial conferences. His research interests include: the life sciences industry; innovation and incentives to encourage medical research and development; antimicrobial resistance (AMR); biosimilars market; the economic returns of medical research; medicines pricing and reimbursement; and policy issues around health technology assessment.
He is an Honorary Visiting Lecturer at the Department of Economics, City University London, and Health Economics Professor at Instituto de Empresa (IE) Business School, Madrid.
David Parkin is Honorary Visiting Professor in the Economics Department at City, University of London. He is an economist who has specialised in health and health care for his entire career, starting with a DPhil at the University of York. His most recent appointment was as Professor of Health Economics in the Division of Health and Social Care Research at King’s College London. He was previously Professor of Economics at City, and has held academic posts at the Medical Schools of the Universities of Newcastle upon Tyne, Aberdeen, and Manchester. From 2009-2013, he was Chief Economist at a Strategic Health Authority within the National Health Service, where his role was to develop, promote, and support economic thinking and analysis throughout the region covered by the Authority.
He has authored many published articles and book chapters in health economics and is co-author of a popular textbook in health economics, Economic Analysis in Health Care. He is a member of the EuroQol group, the owner and developer of the EQ-5D, the world’s most widely used health-related quality of life measurement instrument. From 1998-2011, he organised and led the UK’s Health Economists’ Study Group.